



Disclaimer:

The views, opinions, and content expressed in this presentation do not necessarily reflect the views, opinions, or policies of the Center for Mental Health Services (CMHS), the Substance Abuse and Mental Health Services Administration (SAMHSA), or the U.S. Department of Health and Human Services (HHS).

integration.samhsa.gov

.

How to ask a question during the webinar



If you dialed in to this webinar on your phone please use the "raise your hand" button and we will open up your lines for you to ask your question to the group. (left)

If you are listening to this webinar from your computer speakers, please type your questions into the question box and we will address your questions. (right)

SESSION IS
BEING RECORDED



integration.samhsa.gov

Slides for today's CoP are available on the CIHS website at:

http://www.integration.samhsa.gov/mai-coc-granteesonline-community/communities-of-practice


integration.samhsa.gov

_


Today's Agenda

- 1. Welcome and Introductions
- 2. Innovations in HIV Prevention
- 3. Innovations in Viral Hepatitis Prevention
- 4. Group Discussion

integration.samhsa.gov



What is PrEP?



https://www.cdc.gov/actagainstaids/pdf/campaigns/starttalking/stsh-prep-infographic-basics.pdf

integration.samhsa.gov

How PrEP works



integration.samhsa.gov

_

PrEP History

- Combination drug (TDF and FTC) known as Truvada approved in 2012
 - · Interim guidelines followed
- Comprehensive Clinical guidelines released in 2014 by US Public Health Service
- In all studies risk of HIV infection was 92% lower
 - https://www.cdc.gov/hiv/research/biomedicalresearch/prep/ind ex.html

https://www.cdc.gov/hiv/pdf/PrEP_fact_sheet_final.pdf

integration.samhsa.gov

Poll

At my organization we have:

- A. Never discussed or considered implementing PrEP
- B. Discussed and formally considered implementing PrEP
- C. Started the process of training staff and implementing PrEP
- D. Implemented providing PrEP to our clients

integration.samhsa.gov

11

PrEP Guidance

Summary of Guidance for PrEP Use			
	Men Who Have Sex With Men	Heterosexual Women and Men	Injection Drug Users
Detecting substantial risk of acquiring HIV infection:	Sexual partner with HIV Recent bacterial STD High number of sex partners History of inconsistent or no condom use Commercial sex work	Sexual partner with HIV Recent bacterial STD High number of sex partners History of inconsistent or no condom use Commercial sex work Lives in high-prevalence area or network	HIV-positive injecting partner Sharing injection equipment Recent drug treatment (but currently injecting)
Clinically eligible:	Documented negative HIV test before prescribing PrEP No signs/symptoms of acute HIV infection Normal renal function, no contraindicated medications Documented hepatitis B virus infection and vaccination status		
Prescription	Daily, continuing, oral doeses of TDF/FTC (Truvada), ≤90 day supply		
Other services:	 Follow-up visits at least every 3 months to provide: HIV test, medication adherence counseling, behavioral risk reduction support, side effect assessment, STD symptom assessment At 3 months and every 6 months after, asses renal function Every 6 months test for bacterial STDs 		• •
	Do oral/rectal STD testing	Assess pregnancy intent Pregnancy test every 3 months	Access to clean needles/ syringes and drug treatment services

 $Source: US\ Public\ Health\ Service.\ Preexposure\ prophylaxis\ for\ the\ prevention\ of\ HIV\ infection\ in\ the\ United\ States\ -2014: a\ clinical\ practice\ guideline.$

integration.samhsa.gov

The Guidance: What's missing?



integration.samhsa.gov

13

Team Approach

- How every staff member matters with PrEP:
 - Front desk personnel knowledgeable and nonjudgmental
 - · BH providers supporting healthy decision making
 - · PCPs asking open ended questions
 - Wellness staff increasing self-efficacy
 - Peers at all levels of organization supporting clients and informing organizational best practices

integration.samhsa.gov

PrEP case study

Think through which of the following clients are highest and lowest risk for HIV:

- Transgender South Asian woman >30 with long-term monogamous husband
- 2. White woman <35 with non-monogamous husband
- Heterosexual African American Male >25 with history of not using condoms
- 4. White male <50 struggling with depression and IDU
- 5. Latino MSM with HIV+ male partner who is virally suppressed.

integration.samhsa.gov

15

No Simple Answers

- · Demographics can be less important than behavior
- To Rx PrEP asking open ended questions is key
 - · Be cautious of assuming risk profiles
 - Heterosexuals and those struggling with IDU are PrEP candidates
- · Be flexible with your clients
 - · Sometimes PrEP is the right choice, sometimes it may not be

integration.samhsa.gov

Poll

What are your biggest challenges to implementing PrEP?

- A. Current HIV screening practices
- B. Institutional buy-in
- C. Adherence
- D. Retention
- E. Cost

integration.samhsa.gov

.

Additional Challenges

- Interactions with other medications
 - lithium, pain or arthritis medicines, IV antibiotics, antiviral medicines, cancer medicines, herpes medications
- Age
 - PrEP is yet approved for those younger then 18, however Truvada has been used to treat HIV for that same population
- Cost
- · Client buy-in
- · Condom usage
- Time



integration.samhsa.gov

Opportunities for success

- · Educating clients and providers
- Funding opportunities
 - · VA, Medicare and some insurance providers
- Client advisory board
- Peer support
- Comprehensive behavioral health approaches



integration.samhsa.gov


. .

PrEP in Your Toolkit for HIV Prevention

- PrEP can be part of your HIV prevention toolkit options
- · Prevention and risk reduction plans are flexible
 - · The goal is improved client health
 - Even with PrEP, train that condoms are needed to prevent hepatitis, and other STDS
- Train and educate clients to refrain from substance use
- · Retention, Retention!



integration.samhsa.gov



Key Differences Among Hepatitis A, B, and C

Hepatitis A virus (HAV)

- <2,000 new cases in the US annually
- Preventive vaccine available often recommended for travel overseas

Hepatitis B virus (HBV)

- 850,000 chronically infected in the United States Preventive vaccine available
- Long-term viral suppression is the treatment goal


Hepatitis C virus (HCV)

- > 3million chronically infected in the US
- · NO available vaccine
- Can be **cured** in >90% of patients

http://www.cdc.gov/hepatitis/

integration.samhsa.gov


Viral Hepatitis Populations of Interest – Beyond Baby Boomers




Impact of HBV Infection

- Approximately 850,000 living with chronic HBV infection in the United States
 - 15-25% of people with chronic infection develop serious liver problems
- HBV is 50-100 times more infectious than HIV
- Approximately 3,000 deaths annually
- ~1,000 infants are infected perinatally each year

integration.samhsa.gov






Screening Recommendations for HBV

- PWID
- MSM
- Needle-sharing or sexual partners of persons infected with HBV
- PLWH
- · All pregnant women

 Persons born in regions with high rates of HBV



integration.samhsa.gov

~~

Adult Hepatitis B Vaccination Rates are Suboptimal

- Only 25% of adults 19 year and older are vaccinated against hepatitis B¹
- An estimated 25% to 44% of those at high risk for hepatitis B infection (e.g., MSM, PWID) are vaccinated¹

1. Williams WW, et al. Centers for Disease Control and Prevention (CDC). Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. MMWR Surveill Summ. 2016;65(1):1-36.

integration.samhsa.gov

Barriers to HBV Screening and Vaccination

- Awareness
- Target population identification
- · Cultural/language barriers
- · Perception of risk/low prioritization
- · Interpretation of HBV screening results
- · Completion of HBV vaccine series

integration.samhsa.gov


00


Impact of HCV Infection


- Over 3 million in the US are chronically infected
- For every 100 people infected with HCV:
 - 75-85 develop chronic infection
 - 60-70 develop chronic liver infection
 - 5-20 develop cirrhosis
 - 1-5 will die from liver cancer or cirrhosis
- Chronic hepatitis C infection is also associated with neurological and psychological symptoms

Armstrong et al. Ann Intern Med, 2006; HCV FAQs for Health Professionals, http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1

integration.samhsa.gov







Recommendations for HCV Screening

One time screening test for persons born 1945-1965 (baby boomers)


- · Major risk past or present injection drug use
- · Other risks
 - Received blood/organs prior to June 1992
 - Received blood products made prior to 1987
 - · Ever on chronic hemodialysis
 - · Infants born to HCV infected mothers
 - · Intranasal drug use
 - Unregulated tattoo
 - History of incarceration
- Medical
 - · Persistently elevated ALT (liver enzymes)
 - HIV infection (annual testing)



MMWR Aug 2012. Moyer VA, Ann Int Med 2013.

integration.samhsa.gov

The HCV Care Continuum



[] Calculated as estimated number will access to Supplied nate (1,514,667) x estimated percentage wor on high with reversible (36,7%), 1–555,883.

[**Calculated as estimated number will access to Supplied nate (1,514,667) x estimated percentage prescribed HCV treatment (36,7%), 1–555,883.

**Calculated as estimated number proceded HCV treatment (35,683) x estimated percentage prescribed HCV treatment (35,783).

**Calculated as estimated number proceded HCV treatment (35,683) x estimated percentage prescribed HCV treatment (35,783).

**Note: Only non-VA studies are included in the above HCV treatment ascade.

**Note: Only non-VA studies are included in the above HCV treatment ascade.

Yehia B, Schranz A, Umscheid, C, et al. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. *PLoS One*. 2014;9(7): e101554.





integration.samhsa.gov

_

Barriers to HCV Screening and Treatment

- Awareness
- Target population identification
- Perception of risk/low prioritization
- · Concomitant risk behaviors
- Need for confirmatory testing
- · Perceptions of treatment
- · Access to treatment

integration.samhsa.gov

Hepatitis C Prevention – A Lifelong Approach?

- Hepatitis C infection can be cured in over 90% of individuals
- There is no lifelong immunity reinfection is possible
- Ongoing prevention strategies are needed for those at continued risk

integration.samhsa.gov

37

Viral Hepatitis Resources









- HHS National Viral Hepatitis Action Plan 2017-2020
- The ABCs of Hepatitis
- TIP 53: Addressing Viral
 Hepatitis in People with
 Substance Use Disorders
- Guide to Comprehensive Hepatitis C Counseling and Testing

integration.samhsa.gov

Comprehensive Strategies to Addressing Viral Hepatitis

Prevention

- · Increase provider and public awareness
- · Address risk behaviors
- Vaccination

Screening & Diagnosis

- · Routinize screening protocols
- Ensure confirmatory diagnoses
- · Support healthy behaviors

integration.samhsa.gov

Q&A and Group Discussion





integration.samhsa.gov

MAI-COC Community of Practice Session #2: Sharing Integration Innovations

Thursday, March 30 3:00 - 4:30 PM ET

https://attendee.gotowebinar.com/register/608678350219 1416066

integration.samhsa.gov

40

For More Information & Resources

Visit <u>www.integration.samhsa.gov</u> or e-mail <u>integration@thenationalcouncil.org</u>



integration.samhsa.gov

